Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice

Abstract

loading...

About

This paper, published in 1950, received 227 indexed citations. Written by Qinyu Wang, Guomin Hu, Cong Wen, Cong Chen, Lu Xu, Jiawei Xie, Hui Dai, Han Xiao, Youyi Zhang and Rong Qi covering the research area of Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. It is primarily cited by scholars working on Epidemiology (123 citations), Molecular Biology (107 citations) and Endocrinology, Diabetes and Metabolism (56 citations). Published in British Journal of Pharmacology.

Countries where authors are citing Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice

Since Specialization
Citations

This map shows the geographic impact of Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice more than expected).

Fields of papers citing Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1111/bph.14938.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026